Particle.news
Download on the App Store
4 ARTICLES
·
5h ago

GLP-1 Drugs Linked to Lower Overall Cancer Risk in Overweight and Obese Adults, Study Finds

Researchers urge randomized trials to determine if benefits are drug-specific rather than driven by weight loss.

Image
Hands in blue surgical gloves holding Ozempic injection pen.
Image
Image

Overview

  • An analysis in JAMA Oncology of 86,632 adults in the OneFlorida+ network found a 17% relative reduction in overall cancer incidence among GLP-1 users versus matched nonusers.
  • Significant associations showed lower risks for endometrial, ovarian and meningioma cancers among people taking GLP-1 receptor agonists.
  • Investigators observed a numerically higher, borderline kidney cancer signal (HR ≈ 1.38; 95% CI 0.99–1.93), with indications it was greater in patients younger than 65.
  • The retrospective, propensity-matched design cannot rule out confounding, event counts were low for some cancers, and the study lacked longitudinal BMI data to separate drug effects from weight-loss effects.
  • Authors and commentators cite biological plausibility for risk reduction and recommend longer follow-up, mechanistic research and trials, with clinicians considering careful risk–benefit assessment and kidney monitoring.